We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.6B
AUM Growth
+$272M
Cap. Flow
+$580M
Cap. Flow %
22.28%
Top 10 Hldgs %
59.11%
Holding
341
New
89
Increased
83
Reduced
62
Closed
85

Top Buys

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$32.4M
2
AZN icon
AstraZeneca
AZN
+$11.6M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$10.4M
4
QRHC icon
Quest Resource Holding
QRHC
+$8.96M
5
MBOT icon
Microbot Medical
MBOT
+$7.86M

Top Sells

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$64.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$53.7M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.3M
5
OPK icon
Opko Health
OPK
+$10.5M

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.32%
2 Healthcare 6.56%
3 Energy 0.47%
4 Consumer Discretionary 0.36%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
26
PUT
Merck
MRK
$357B
$16.6M 0.64%
2,932
+2,618
+834% +$147K
ACHC icon
27
Acadia Healthcare
ACHC
$2.64B
$16.4M 0.63%
+663,324
New +$32.4M
AMGN icon
28
CALL
Amgen
AMGN
$206B
$15.5M 0.59%
+1,103
New +$144K
PFE icon
29
CALL
Pfizer
PFE
$158B
$15.3M 0.59%
+5,439
New +$153K
MNKD icon
30
PUT
MannKind Corp
MNKD
$1.21B
$15.1M 0.58%
5,110
+1,075
+27% +$42.4K
AGN
31
DELISTED
Allergan plc
AGN
$15M 0.58%
62,233
+28,857
+86% +$6.46M
ACHN
32
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$14.2M 0.54%
14,215
-1,772
-11% -$16.4K
IOC
33
DELISTED
Interoil Corporation
IOC
$12.2M 0.47%
223,979
+92,185
+70% +$5.38M
BMY icon
34
PUT
Bristol-Myers Squibb
BMY
$131B
$12.1M 0.46%
2,359
+465
+25% +$23.2K
AUXL
35
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$11.5M 0.44%
3,847
+8
+0.2% +$170
UTHR icon
36
CALL
United Therapeutics
UTHR
$21.3B
$11.2M 0.43%
870
+481
+124% +$49.6K
TENX icon
37
Tenax Therapeutics
TENX
$69.6M
$11M 0.42%
88
+3
+4% +$385K
BIIB icon
38
PUT
Biogen
BIIB
$32.1B
$10.8M 0.42%
327
-150
-31% -$49.5K
SGMO
39
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$10.8M 0.41%
10,012
– –
GEVA
40
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$9.99M 0.38%
+145,200
New +$10.4M
GEVA
41
PUT
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$9.99M 0.38%
1,452
+121
+9% +$8.66K
REGN icon
42
CALL
Regeneron Pharmaceuticals
REGN
$80.5B
$9.73M 0.37%
270
-896
-77% -$300K
A icon
43
PUT
Agilent Technologies
A
$41.4B
$9.48M 0.36%
+2,325
New +$94.9K
PBYI icon
44
CALL
Puma Biotechnology
PBYI
$471M
$8.54M 0.33%
358
+283
+377% +$58.1K
TSLA icon
45
Tesla
TSLA
$1.42T
$7.93M 0.3%
489,945
+166,590
+52% +$2.75M
COV
46
PUT
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$7.89M 0.3%
+912
New +$80.8K
AMGN icon
47
PUT
Amgen
AMGN
$206B
$7.71M 0.3%
549
-564
-51% -$73.6K
TEVA icon
48
PUT
Teva Pharmaceuticals
TEVA
$45.1B
$7.61M 0.29%
1,416
-14,158
-91% -$750K
SRPT icon
49
CALL
Sarepta Therapeutics
SRPT
$2.16B
$7.54M 0.29%
3,574
+1,936
+118% +$43.7K
PRQR icon
50
ProQR Therapeutics
PRQR
$262M
$6.55M 0.25%
+381,249
New +$6.11M
1
2
3 4 5

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sabby Management held 341 positions worth $2.6B, up 12% from $2.33B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management deployed $580M of net new capital in Q3 2014, opening 89 new positions and adding to 83 existing holdings. Its largest new stake was Acadia Healthcare: 663,324 shares worth $16.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 92% of assets, up from 87% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was SALIX PHARMACEUTICALS LTD DEL, an estimated $6.87M trimmed.

  • Sabby Management's largest Q3 2014 buy was Acadia Healthcare: 663,324 shares worth $16.4M.
  • Sabby Management added most to AstraZeneca in Q3 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $6.87M.
  • Sabby Management fully exited Weyerhaeuser in Q3 2014, selling an estimated $64.6M.
  • Sabby Management's ten largest holdings make up 59% of its $2.6B portfolio in Q3 2014.
  • Sabby Management opened 89 new positions and closed 85 in Q3 2014.
  • Sabby Management's portfolio value rose 12% quarter-over-quarter to $2.6B.

Based on Sabby Management's 13F filing for Q3 2014, filed 14 Nov 2014.